Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.
Weight Loss From GLP-1 Drugs Not As Robust In Real-World Settings
In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.
GLP-1 Weight Loss Drugs May Interfere With Endoscopy And Colonoscopy Procedures, Warns Study
A new study published in the journal JAMA Network Open found that food left in the stomach or stool left in the bowel can hinder a doctor’s ability to successfully perform an endoscopy or colonoscopy.
GLP-1 weight-loss meds might interfere with endoscopy, colonoscopy
Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or stool left in the bowel before an endoscopy or colonoscopy.
Weight-loss surgery may preserve kidney health more effectively than GLP-1 drugs
People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 drugs when it comes to preserving kidney function, a new study finds.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The announcement is a blow to the compounding pharmacies that have made cheaper, off-brand versions of the medication The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over,
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
England's NHS to offer Lilly's weight-loss drug to some patients
England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a three-year plan, the country's drugs cost regulator said on Thursday. The drug,
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.
21h
GLP-1 medications, their effect on bariatrics and cautions for people seeking weight loss without surgery
Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...
1d
Social media algorithms are driving the GLP-1 drugs boom
GLP-1 receptor agonists are being recommended on social media, raising questions about who can see the content and what the ...
2d
GLP-1 supplements promise to curb cravings and promote weight loss. Experts are skeptical.
GLP-1 supplement makers claim that their products work similarly to weight loss injections like Ozempic. Here's what experts ...
Healthline
13d
Ozempic: GLP-1 Drugs May Help Prevent 34,000 Heart Attacks and Strokes Per Year
GLP-1 drugs like Ozempic and Wegovy may help reduce the risk of cardiovascular disease and prevent more than 34,000 heart ...
FiercePharma
21h
Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
MedPage Today
8d
The Data Are Clear: Patients Regain Weight After Stopping GLP-1 Drugs
Looking at the data from clinical trials of new
GLP-1
agonists, it's clear that patients will need to stay on the
drugs
to maintain their weight loss, experts said. At the same time, there's a ...
1d
Social media algorithms are driving the the GLP-1 drugs boom
GLP-1 receptor agonists are being recommended on social media, raising questions about who can see the content and what the ...
18h
on MSN
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Novo Nordisk
Feedback